Pre Market
|
||||
|
|
|
|
Regular Hours (Closed)
|
|
|
|
|
||||||||||||
|
|
|
|
|
|
|
|
| Valuation Estimation |
|
EPS (Current/Estimated)
-1.40/-1.11
|
|
Enterprise Value
516.79M
|
| Balance Sheet |
|
Book Value Per Share
1.82
|
| Cash Flow |
|
Cash Flow Yield
--
|
| Income Statement |
|
Total Revenue
0
|
|
Operating Revenue Per Share
0.09
|
|
Industry Comparison
|
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Industry overview quotes are at least 15 minutes delayed (Except Overnight Trading Session)
|
Business Description
|
|||
| Perspective Therapeutics Inc is a radiopharmaceutical development company that is pioneering advanced treatment applications for cancers throughout the body. The Company has a proprietary technology that utilizes the alpha-emitting isotopeLead-212 (212Pb) to deliver powerful radiation specifically to cancer cells via specialized targeting moieties. |

4.34 

4.27